Age-specific analysis of Trastuzumab Deruxtecan in HER2+ mBC.

A study analyzed the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (mBC) patients of different age groups, using data from the DESTINY-Breast01, -02, and -03 trials, revealing valuable insights into T-DXd's use across varying ages.

5 months 28 Views

Ian Krop, MD, PhD - Yale University

This study conducted an age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (mBC) using data from the DESTINY-Breast01, -02, and -03 trials. The analysis aimed to evaluate the efficacy and safety of T-DXd across different age groups. The results provide valuable insights into the use of T-DXd in HER2-positive mBC patients of varying ages.